IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells
about
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor MicroenvironmentTherapeutic cancer vaccines: past, present, and futureReciprocal relationship between myeloid-derived suppressor cells and T cellsMyeloid-derived suppressor cells as therapeutic target in hematological malignanciesTh17 Cell Plasticity and Functions in Cancer ImmunityTargeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer TypeInterplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentDysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor ImmunityCrosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor MicroenvironmentImmature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cellsIL-17 mediated inflammation promotes tumor growth and progression in the skinPancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.The Treg/Th17 paradigm in lung cancerT cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model.Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicityInterleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophagesIntratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients.Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patientsElevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy.Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.IL-17 enhances tumor development in carcinogen-induced skin cancer.Th17 cells in cancer: help or hindrance?The role of cytokines in breast cancer development and progressionMyeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune diseaseTGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanismsImmunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARδ in inflammation-induced colon carcinogenesis.Prognostic significance of interleukin-17 in solid tumors: a meta-analysis.Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17(+) γδ T cells in a murine model for HPV associated cancer.γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.Essentials of Th17 cell commitment and plasticityInterleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models.Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus.
P2860
Q26799126-33A8E22D-3F95-48BF-8E8B-2CBBD57D0794Q26863283-AD1FE0D2-45C6-4DB6-90DB-CBAF73934F33Q27000664-D7A718EC-1C94-444E-8F36-78819FE9DB51Q27010234-6FBBC7C1-36BB-4257-9C7D-FDF20862C44AQ27012901-A7193E05-8495-42F7-82B3-81AD1D5BB55DQ28066522-570030AD-B8C2-4231-922D-A5CC10E65621Q28070110-10F4891D-BE5E-4AEA-8702-3331216A7367Q28071935-3C336CD9-FDF1-4E12-8B11-703E0C00005DQ28075996-709227F4-6C46-4E6C-8227-85EEC2AE5CF0Q28077126-BA651662-E10F-4546-94A1-EEB2658E3136Q28256749-CE15625D-E30D-46C7-A5B0-67D1D1694144Q28480915-C70E7A8B-5F96-4333-902C-AC9283FB8737Q33560501-26064AE6-6EE9-47B2-9E50-69490DE02F6DQ33606107-06807180-AAA8-4C76-AE3F-BF555C679318Q33608606-395F88FD-E33F-4381-9FC7-63E138634C64Q33685236-D32FF670-294C-48EE-9E83-1553852F414CQ33698636-72F5D19E-A543-4486-B43A-031FF456354EQ33777002-F746E158-77FB-42E9-B291-94A611EEC261Q33810570-95BF0E8C-6EB3-40AC-BE2A-6DA49EE5D18EQ33961542-78443B52-558B-4C18-81DD-80FDB75CA7E1Q34043416-4842DFEB-86DA-4077-8044-548BF217971DQ34081723-04F52E3C-DA5C-4320-B2B7-08332F5D48E2Q34119854-3B633321-9E3D-41AC-B978-F94B3D50A0DBQ34149842-3D76F0BA-09AD-4C60-B5AB-E03535207C52Q34487114-71D81500-713B-4AA2-A348-B76FE9B30865Q34506935-AB14109D-F5C7-4048-B8AC-754FAFB10404Q34570874-5BE9F19C-6F8A-4259-A01A-E324A0C9E75BQ34690808-FC2BA982-1EB9-470A-BD58-95E1F72C0C5CQ34913808-0DFECFB2-54A7-40D1-89E6-59529CE3F2CDQ34920381-3251A120-9B0C-4A53-AB1E-D467D020FBCDQ35115477-CE418AE8-8B8B-4442-B08B-AEC0209E4424Q35814020-E9C0B9EC-D8C4-491A-BDF0-2CEB5362FA2AQ35939357-B202C476-3063-445A-B931-5AFC7005414CQ36046142-1961D0FF-BB7D-43B6-A5EE-0F98C84E5082Q36373342-1AFE94EE-D109-45FD-8BD3-C86308646E8DQ36473289-E8CAF1FF-74DB-4A99-AF11-B41E059A8BC7Q36730400-13280351-9321-41CA-AAF3-B0A26F168118Q36879626-47C10319-8823-4DE1-8276-730F5BFC57B7Q36967364-6DD186E9-8250-42E1-9443-0B621C105829Q36974463-B03ED295-AF3A-4FFF-8372-3EE0F6C48FAF
P2860
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@ast
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@en
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@nl
type
label
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@ast
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@en
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@nl
prefLabel
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@ast
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@en
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@nl
P2093
P2860
P356
P1476
IL-17 promotes tumor developme ...... eloid-derived suppressor cells
@en
P2093
Craig A Elmets
Donggou He
John D Mountz
Nabiha Yusuf
P2860
P304
P356
10.4049/JIMMUNOL.0902574
P407
P577
2010-01-29T00:00:00Z